Journal Article

Inhibition of iRhom1 by CD44-targeting nanocarrier for improved cancer immunochemotherapy

Li, Song, Wang, Qiming Jane, Sun, Jingjing, Lu, Binfeng, Chen, Yuang, Yang, Da, Chen, Chien-Yu, Huang, Yixian, Wang, Zehua, Huang, Haozhe, Li, Lu-Yuan, Batra, Neelu, Wang, Yifei, Li, Shichen, Zhang, Ziqian, Luo, Zhangyi, Conway, James F., Yu, Ai-Ming

2024

Overview

The multifaceted chemo-immune resistance is the principal barrier to achieving cure in cancer patients. Identifying a target that is critically involved in chemo-immune-resistance represents an attractive strategy to improve cancer treatment. iRhom1 plays a role in cancer cell proliferation and its expression is negatively correlated with immune cell infiltration. Here we show that iRhom1 decreases chemotherapy sensitivity by regulating the MAPK14-HSP27 axis. In addition, iRhom1 inhibits the cytotoxic T-cell response by reducing the stability of ERAP1 protein and the ERAP1-mediated antigen processing and presentation. To facilitate the therapeutic translation of these findings, we develop a biodegradable nanocarrier that is effective in codelivery of iRhom pre-siRNA (pre-siiRhom) and chemotherapeutic drugs. This nanocarrier is effective in tumor targeting and penetration through both enhanced permeability and retention effect and CD44-mediated transcytosis in tumor endothelial cells as well as tumor cells. Inhibition of iRhom1 further facilitates tumor targeting and uptake through inhibition of CD44 cleavage. Co-delivery of pre-siiRhom and a chemotherapy agent leads to enhanced antitumor efficacy and activated tumor immune microenvironment in multiple cancer models in female mice. Targeting iRhom1 together with chemotherapy could represent a strategy to overcome chemo-immune resistance in cancer treatment. A pro-tumorigenic role of iRhom1 has been described in several cancer types. Here the authors show that iRhom1 regulates sensitivity to chemotherapy and immune response, as well they report that CD44 targeting nanoparticle-mediated co-delivery of iRhom1 pre-siRNA promotes anti-tumor immune responses in preclinical cancer models.

• Publisher: Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
• Subject: 13 / 13/109 / 13/44 / 13/89 / 38 / 38/39 / 59 / 59/5 / 631/154/152 / 631/61/391 / 631/67/1059 / 631/67/580 / 64 / 64/60 / 82/80 / 96 / 96/109 / 96/31 / 96/34 / 96/95 / Aminopeptidases / Animal models / Animals / Anticancer properties / Antigen presentation / Antigen processing / Antitumor activity / Biodegradation / Cancer / Cancer therapies / CD44 antigen / Cell Line, Tumor / Cell Proliferation / Chemotherapy / Cytotoxicity / Drug Carriers / Endothelial Cells / ERAP1 protein / Female / Hsp27 protein / Humanities and Social Sciences / Humans / Hyaluronan Receptors / Immune response / Immune system / Immunosuppressive agents / Immunotherapy / Lymphocytes T / Membrane Proteins / Metastases / Mice / Microenvironments / Minor Histocompatibility Antigens / multidisciplinary / Nanoparticles / Neoplasms - drug therapy / Permeability / Science / Science (multidisciplinary) / Sensitivity / siRNA / Tumor cells / Tumors